Australia's Race Oncology jumps on positive feedback from U.S. FDA

Racura Oncology

23/11/2022 02:43

** Shares of Race Oncology  RAC.AX  leap as much as 8% to
A$2.44, their best intraday gain since Oct. 18
    ** Co says U.S. FDA gives "clear guidance" for further U.S.
trials on Zantrene, being developed to treat for melanoma and
clear cell renal cell carcinoma
    ** Says the guidance is "highly encouraging," adding that
though no U.S. trials planned in short- or medium-term, it is
"extremely valuable" to have the option
    ** FDA also said outstanding clinical hold issues from RAC's
earlier new drug application (NDA) submitted in 2019 been
adequately addressed
    ** RAC down 37.2% YTD, as of last close
 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))